Connecticut’s governor has signed a bill to expand a pilot program that’s meant to explore the therapeutic potential of psychedelics such as psilocybin and MDMA.
The legislation sponsored by the Joint Committee on Public Health cleared the House of Representatives in 122-27 vote last month after passing the Senate by a unanimous 35-0 vote in April.
Gov. Ned Lamont (D) signed it into law on Thursday.
The new law builds upon an existing psychedelic-assisted therapy program involving military veterans and first responders who elect to participate in clinical trials.
It also repeals and replaces the current statute to make it so any adults 18 or older who meet clinical eligibility criteria established by the institutional review board of the medical school selected to administer the pilot program could be eligible to receive psychedelics treatment in a clinical setting, with researchers tasked with studying the efficacy of the novel therapeutics.
It additionally removes existing language stipulating that the pilot program must end upon federal approval of psilocybin or MDMA by the Drug Enforcement Administration (DEA) or a successor agency.
Finally, it strikes outdated language requiring the state Department of Mental Health and Addiction Services to create and facilitate the program by
Read full article on Marijuana Moment
